Yoshimi Tanaka

Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3–Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3–Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Trial

Ian E. Krop, Norikazu Masuda, Toru Mukohara et al. · Journal of Clinical Oncology · 2023 · 122 citations · Full text

Medicine, Oncology, Pharmacology +15

Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC).

Ian E. Krop, Norikazu Masuda, Toru Mukohara et al. · Journal of Clinical Oncology · 2022 · 66 citations

Medicine, Oncology, Pharmacology +17

Prognostic benefit of surgical management in renal cell carcinoma patients with thrombus extending to the renal vein and inferior vena cava: 17-year experience at a single center

Shingo Hatakeyama, Itsuto Hamano, Hiromi Murasawa et al. · BMC Urology · 2013 · 61 citations · Full text

Medicine, Oncology, Surgery +14

Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC

Helena A. Yu, Christina S. Baik, D.-W. Kim et al. · Annals of Oncology · 2024 · 44 citations · Full text

Medicine, Oncology, Pharmacology +16

Development of Underwater Laser Cladding and Underwater Laser Seal Welding Techniques for Reactor Components

Takehisa Hino, M. Tamura, Yoshimi Tanaka et al. · Journal of Power and Energy Systems · 2009 · 35 citations · Full text

Engineering, Materials Science, Nuclear Engineering +17